Factors associated with loss to follow-up of outpatients with depression in general hospitals

Jingjing Zhang¹ and Chenyu Ye²

Abstract
Objective: We aimed to understand the reasons behind outpatient loss to follow-up and the views of Chinese patients with depression regarding disease diagnosis and antidepressant therapy.

Methods: Consecutive outpatients with newly diagnosed depressive disorder between September 2012 and August 2013 at the Shanghai First People’s Hospital (a tertiary hospital) were categorized into follow-up and lost-to-follow-up groups. We collected information on demographics, the Hamilton depression (HAMD) scale, Self-Rating Depression Scale (SDS), Self-Rating Anxiety Scale, and Symptom Checklist-90. Patients were routinely followed at 2, 4, 8, and 12 weeks. Any missed appointment was considered lost to follow-up.

Results: After 12 weeks of treatment, only 42.2% (70/166) of patients were continuing follow-up. Patients lost to follow-up were significantly younger (median, 42.5 vs. 56.5 years), had different marital status, higher education level, higher SDS score (43.8 ± 10.8 vs. 40.2 ± 10.9), and higher HAMD score (median, 21 vs. 19). Age (odds ratio (OR) = 0.97, 95% confidence interval (CI): 0.95–0.997), and HAMD score (OR = 1.14, 95% CI: 1.01–1.29) were independently associated with loss to follow-up.

Conclusion: Young age, higher HAMD score, and poor knowledge of depression and treatment were the main factors associated with loss to follow-up during depression management among our Chinese patients.

Keywords
Outpatient, depression, psychiatry department, loss to follow-up, discontinuation, China

Date received: 24 December 2019; accepted: 17 April 2020
Introduction

In China, the lifetime prevalence of major depressive disorder is 3.3% to 3.6%. Most patients do not receive antidepressant treatment in accordance with the guidelines, and their depressive symptoms relapse. A main cause of relapse is non-adherence to treatment. Patients with poorly managed and relapsing depression are at higher risk of complications such as suicidal ideation, social strain, loss of workdays, reduced quality of life, cognitive impairment, and mortality. Apart from non-adherence to antidepressives, loss to follow-up is another form of non-adherence to treatment as regular patient assessment and discussions with a psychiatrist are part of optimal patient management of depression.

Many studies outside China have focused on antidepressant adherence. Sexual side effects, low self-efficacy, female sex, and low education level are the primary reasons for low treatment adherence. In China, most patients with depression are not treated according to the guidelines but instead have short treatment courses and low persistence with treatment. In Chinese patients with depression, depression itself seems to be the main reason for discontinuing treatment; however, these results need to be refined, to improve our understanding of the factors that could predict a loss to follow-up.

In the present study, we aimed to understand the reasons behind outpatient loss to follow-up and the views of Chinese patients with depression regarding disease diagnosis and antidepressant therapy.

Methods

Study design and participants

This was a retrospective study including consecutive outpatients (age 18–75 years) with newly diagnosed depressive disorder at the Shanghai First People’s Hospital (a tertiary hospital) between September 2012 and August 2013. The diagnosis of depression was made according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The inclusion criteria included Hamilton depression (HAMD) scale score ≥ 17. The exclusion criteria were: 1) patients with bipolar depression or anxiety disorders owing to organic diseases; 2) other functional mental disorders; and 3) serious physical diseases. This study was approved by the ethics committee of the Shanghai First People’s Hospital. All patients signed an informed consent form.

Grouping

As per routine practice at this hospital, the patient and physician agreed on the date of the following appointment at each visit. Loss to follow-up was defined as failing to present to the appointment, failing to present for up to 2 weeks after the planned date, and no subsequent appointment being made. During the study period, patients who missed a single visit were categorized as the lost-to-follow-up group.

Data collection

Validated Chinese versions of the HAMD scale, Self-Rating Depression Scale (SDS), Self-Rating Anxiety Scale (SAS), Symptom Checklist-90 (SCL-90), and depression factor (Dep factor) of the SCL-90 were administered routinely at each visit, which were at 2, 4, 8, and 12 weeks, as per routine practice. The characteristics (demographic and socioeconomic factors) of patients and their treatments were collected from the medical charts.

Survey

As per routine practice at our institution, when a patient is considered lost to
follow-up, attempts are made to reach the patient and ascertain the reasons for missing follow-up appointments. Patients are told at the first visit that this is the standard procedure, in case the patient refuses follow-up visits. We developed a survey based on the feedback of 37 patients with depression (15 men and 22 women), as well as the relevant literature.\textsuperscript{11,22} Consistency among assessors was good (kappa of 0.80).

**Statistical analysis**

We used SPSS version 11.0 (SPSS Inc., Chicago, IL, USA) for the analysis. Continuous data are expressed as mean ± standard deviation, and categorical data are expressed as frequency. To compare data between groups, the Pearson chi-square test, Student \( t \)-test, and Mann–Whitney U test were used, as appropriate. Multivariable logistic regression was used to analyze the baseline factors affecting loss to follow-up and included the variables identified in the univariate analyses with \( p < 0.05 \). All tests were two-sided and \( p \)-values < 0.05 were considered statistically significant.

**Results**

**Patient characteristics**

During the study, 166 patients were recruited and categorized into two groups on the basis of loss to follow-up; the follow-up group included 70 patients, and the lost-to-follow-up group included 96 patients. Only 42.2% of patients completed the first 12 weeks of treatment, i.e., acute phase treatment. Table 1 presents the characteristics of participants. Patients who were

| Table 1. Characteristics of patients. |
|--------------------------------------|
| Variable                            | Total (N = 166) | Follow-up (N = 70) | Lost to follow-up (N = 96) | P        |
|--------------------------------------|----------------|--------------------|-----------------------------|----------|
| Age, average (range)                 | 50 (16.75)     | 56.5 (25.75)       | 42.5 (16.71)                | <0.001   |
| Sex, n (%)                           |                |                    |                             | 0.962    |
| Male                                 | 43 (25.9%)     | 18 (25.7%)         | 25 (26.0%)                  |          |
| Female                               | 123 (74.1%)    | 52 (74.3%)         | 71 (74.0%)                  |          |
| Marital status, n (%)                |                |                    |                             | <0.001   |
| Married                              | 118 (71.1%)    | 58 (82.9%)         | 60 (62.5%)                  |          |
| Single                               | 32 (19.3%)     | 5 (7.1%)           | 27 (28.1%)                  |          |
| Divorced                             | 11 (6.6%)      | 2 (2.9%)           | 9 (9.4%)                    |          |
| Widowed                              | 5 (3.0%)       | 5 (7.1%)           | 0                           |          |
| Education, n (%)                     |                |                    |                             | 0.020    |
| Primary school and below             | 17 (10.2%)     | 11 (15.7%)         | 6 (6.3%)                    |          |
| Junior high school                   | 65 (39.2%)     | 33 (47.1%)         | 32 (33.3%)                  |          |
| Senior high school                   | 32 (19.3%)     | 10 (14.3%)         | 22 (22.9%)                  |          |
| College and above                    | 52 (31.3%)     | 16 (22.9%)         | 36 (37.5%)                  |          |
| SCL-90 total score*                  | 194 (106,366)  | 187 (106,366)      | 202 (118,342)               | 0.074    |
| Dep factor score*                    | 2.7 ± 0.8      | 2.6 ± 0.7          | 2.7 ± 0.8                   | 0.149    |
| SDS scale score*                     | 42.3 ± 10.9    | 40.2 ± 10.9        | 43.8 ± 10.8                 | 0.033    |
| SAS scale score*                     | 34 (20.59)     | 34 (20.54)         | 34 (20.59)                  | 0.398    |
| HAMD scale score*                    | 20 (17,28)     | 19 (17,27)         | 21 (17,28)                  | 0.001    |

SCL-90: Symptom Checklist-90; Dep factor: depression factor; SDS: Self-Rating Depression Scale; SAS: Self-Rating Anxiety Scale; HAMD: Hamilton Depression Scale.

*Scores are average (range) or mean ± standard deviation.
lost to follow-up were significantly younger (median, 42.5 vs. 56.5 years, P < 0.001), had differing marital status (i.e., married, divorced, and widowed) (P < 0.001), and a higher education level (P = 0.02). There was no difference in the sex distribution. No patients received electroconvulsive therapy because it is not offered at our center. During the study period, no patients were declared to be in remission and discharged by their physician.

Patients who were lost to follow-up had higher SDS scores (43.8 ± 10.8 vs. 40.2 ± 10.9, P = 0.03) and higher HAMD scores (median, 21 vs. 19, P = 0.001). There were no differences in SCL-90, Dep factor, and SAS scores.

**Rates of follow-up and discontinuation at different time points**

The rate of loss to follow-up for outpatients with depression increased gradually over time (Table 2). High loss to follow-up (57.8%, 96/166) was observed at the end of week 12 after the initial visit. Most patients were lost to follow-up at the second visit, with a loss to follow-up rate at week 2 of 39.2% (67.7% of the total lost-to-follow-up group (65/96)); this rate increased to 45.2% at week 4, 53% at week 8, and 57.8% at week 12.

**Univariable and multivariable analyses**

Univariable analyses showed that age (P < 0.001), education (P = 0.02), marital status (P = 0.006), SDS score (P = 0.04), and HAMD score (P = 0.002) were associated with loss to follow-up (Table 3). Multivariable analysis showed that age (OR = 0.97, 95% CI: 0.95–0.997, P = 0.03) and HAMD score (OR = 1.14, 95% CI: 1.01–1.29, P = 0.03) were independently associated with loss to follow-up (Table 3).

**Reasons for loss to follow-up**

Table 4 presents the reasons for loss to follow-up. The main reasons given by patients were “I am worried about the side effects of the medicine” (33/96, 34.4%), “My depression is not a disease and cannot be resolved with medicine” (26/96, 27.1%), “Depression is a natural emotional reaction that does not require therapy” (21/96, 21.9%), and “The drug is effective and I do not need further treatment” (24/96, 25.0%).

**Reasons patients discontinued follow-up at different time points**

As shown in Table 4, before and after week 2, 12.3% and 51.6% of patients, respectively, gave the reason for discontinuing follow-up as “The drug is effective and I do not need further treatment” (P < 0.001).

**Discussion**

In the present study, we aimed to understand the reasons behind outpatient loss to follow-up and the views of Chinese

| Week   | Lost cases (%) | Followed up cases (%) | New lost cases (%) |
|--------|----------------|-----------------------|--------------------|
| Week 2 | 65 (39.2)      | 101 (60.8)            | 65 (67.7)          |
| Week 4 | 75 (45.2)      | 91 (54.8)             | 10 (10.4)          |
| Week 8 | 88 (53.0)      | 78 (47.0)             | 13 (13.5)          |
| Week 12| 96 (57.8)      | 70 (42.2)             | 8 (8.3)            |

*Calculated as % of total cases.
**Calculated as % of cases lost to follow-up.
patients with depression regarding the disease diagnosis and antidepressant therapy. The results suggested that patients with high follow-up adherence were relatively older and had higher HAMD scores. Globally, the main reason for loss to follow-up was the fear of adverse effects and the belief that depression cannot or should not be cured using drugs. The main reason for loss to follow-up after 2 weeks of treatment for depression was the belief that the drug was effective and no longer needed.

Sawada et al. reported that from the first visit to a doctor, the follow-up rate of people with depression was 72.5% at 1 month and 54.0% at 3 months. Vanelli et al. showed that 38.8% of patients who were not receiving antidepressant treatment stopped their follow-up within 30 days after their first visit to the hospital. In the present study, the follow-up rate at 4 weeks was 54.8% and 42.2% at 3 months, which is lower than in previous studies. This could be owing, at least in part, to Chinese cultural traditions in which family support has a very important role in disease management. In addition, depression is considered a shameful disease in China, and patients are often unwilling to seek help or consult with a physician. Yau et al. showed that 46% of patients were noncontinuous users when prescribed a new therapy. Lu et al. showed that lower income, fewer than three episodes of depression, and anxiety were associated with better adherence.

Our results showed that patients who were lost to follow-up were younger than those in the follow-up group, which is supported by a previous study. HAMD scale scores in the lost-to-follow-up group were higher, in contrast to the findings of Lee.

Table 3. Univariable and multivariable analyses of baseline factors associated with loss to follow-up at 3 months.

|                          | Univariate analysis | Multivariate analysis |
|--------------------------|---------------------|-----------------------|
|                          | OR      | 95% CI | P       | OR      | 95% CI | P       |
| Age                      | 0.953   | 0.931  | <0.001  | 0.971   | 0.945  | 0.997   | 0.031  |
| Sex (female vs. male)    | 0.983   | 0.486  | 1.987   | 0.962   | 0.588  | 5.379   | 0.308  |
| Education                | 1.778   | 0.588  | 5.379   | 0.308   | 4.033  | 1.162   | 0.028  |
| Junior high school vs. primary school and below | 4.125 | 1.298  | 13.106  | 0.016   |        |         |        |
| Senior high school vs. primary school and below | 5.220 | 1.882  | 14.479  | 0.002   | 4.350  | 0.901   | 20.995 | 0.067  |
| College and above vs. primary school and below | 4.125 | 1.298  | 13.106  | 0.016   |        |         |        |
| Marital status           |         |        |         |         |        |         |        |
| Single vs. married       | 5.220   | 1.882  | 14.479  | 0.002   | 2.028  | 0.610   | 6.734  | 0.248  |
| Divorced vs. married     | 4.350   | 0.901  | 20.995  | 0.067   | 3.567  | 0.711   | 17.909 | 0.122  |
| Widowed vs. married      | 0.000   | 0.000  | 0.999   | 0.000   | 0.000  | 0.000   | 0.999  |        |
| SCL-90 total score       | 1.006   | 1.000  | 1.012   | 0.066   |        |         |        |        |
| Dep factor score         | 1.340   | 0.900  | 1.995   | 0.149   |        |         |        |        |
| SDS scale score          | 1.032   | 1.002  | 1.063   | 0.035   |        |         |        |        |
| SAS scale score          | 1.017   | 0.982  | 1.053   | 0.335   |        |         |        |        |
| HAMD scale score         | 1.191   | 1.067  | 1.329   | 0.002   | 1.142  | 1.011   | 1.290  | 0.032  |

OR: Odds ratio; CI: confidence interval; SCL-90: Symptom Checklist-90; Dep factor: depression factor; SDS: Self-Rating Depression Scale; SAS: Self-Rating Anxiety Scale; HAMD: Hamilton Depression Scale.
We found that a higher HAMD scale score results in more serious symptoms of depression and these patients are more likely to feel negatively toward therapy. Therefore, in this population, lower HAMD scores were globally associated with more positive attitudes, including attitudes toward therapy. Suicide and remission are other factors that can affect the loss to follow-up rate. Regarding the suicide rate, these data are unreliable because suicide is only recorded in the medical chart if the hospital is informed of the cause of death by the family; this results in considerable underreporting. During the study period, no patients were declared to be in remission and discharged by their physician. Therefore, those two factors did not affect the loss to follow-up rate observed here.

The most common reasons for loss to follow-up were cognitive reasons, i.e., misconceptions about depression and its treatment, as supported by the findings of a previous study. Hung et al. found that 19.3% of their patients did not agree with their diagnosis, 20.2% were worried about side effects, and 8.4% were not confident about medical therapy. By comparison, values for the corresponding reasons in the present study were 27.1%, 34.4%, and 13.5%, respectively. This suggests that in mainland China, insufficient information may be provided to the public about depression, and information dissemination regarding the disease may need further improvement.

**Table 4.** Analysis of the reasons patients discontinue follow-up visits at different time points.

| Reason, n (%) | Total number N = 96 | Lost during week 2 N = 65 | Lost after week 2 N = 31 | P |
|--------------|---------------------|---------------------------|--------------------------|---|
| Depression is a natural emotional reaction that does not require therapy | 21 (21.9%) | 15 (23.1%) | 6 (19.4%) | 0.680 |
| I am depressed because I am not strong | 26 (27.1%) | 21 (32.3%) | 5 (16.1%) | 0.095 |
| My depression is not a disease and cannot be resolved with medicine | 4 (4.2%) | 2 (3.1%) | 2 (6.5%) | 0.820 |
| I will no longer have a normal life | 1 (1.0%) | 1 (1.5%) | 0 | 1.000 |
| My depression is caused by another disease, and it is meaningless to undergo therapy | 33 (34.4%) | 26 (40%) | 7 (22.6%) | 0.093 |
| I am worried about the side effects of the medicine (may deteriorate liver and kidney function or memory loss) | 14 (14.6%) | 12 (18.5%) | 2 (6.5%) | 0.211 |
| The antidepressant will control my mind | 17 (17.7%) | 14 (21.5%) | 3 (9.7%) | 0.155 |
| I am afraid of having drug dependency | 13 (13.5%) | 8 (12.3%) | 5 (16.1%) | 0.847 |
| The antidepressant is not effective, and I do not trust the therapy | 24 (25.0%) | 8 (12.3%) | 16 (51.6%) | <0.001 |
| The drug is effective and I do not need further treatment | 13 (13.5%) | 12 (18.5%) | 1 (3.2%) | 0.085 |
| Budget | 4 (4.2%) | 4 (6.2%) | 0 | 0.387 |
| Traffic | 16 (16.7%) | 10 (15.4%) | 6 (19.4%) | 0.625 |
| Relationship with the medical team | 4 (4.2%) | 4 (6.2%) | 0 | 0.387 |
| Lack of family support | 14 (14.6%) | 8 (12.3%) | 6 (19.4%) | 0.545 |
| Any force majeure incident | 13 (13.5%) | 12 (18.5%) | 1 (3.2%) | 0.085 |
improvement. In China, most patients with depression are not treated according to the guidelines; they have short treatment courses and low treatment persistence. Economic reasons can be a major factor for many Chinese patients, but this was not the case in the present study as all patients were from the Shanghai urban area and had medical insurance. Yau et al. showed that younger age, female sex, living in public housing, side effects, irregular follow-ups, and early-onset diagnosis were associated with treatment non-adherence. Therefore, the main reason affecting treatment is misconceptions about depression and antidepressants. This information should be provided to patients in the outpatient department at different time points, to correct cognitive biases and improve the rate of standardized treatment. With regard to education provided for patients, the following methods may be practical: (1) distribution of leaflets about treatments for depression, to inform the public about the availability of medical treatment; (2) increasing the number of follow-up phone calls to understand patients’ actual feelings or concerns about depression; and (3) organizing group activities to enable patients to exchange their views or feelings about their treatment. In this way, more appropriate guidance can be provided. Nevertheless, further studies are needed to determine the effectiveness of these educational tools and follow-up visits in improving medication adherence among patients with depression in China.

This study has some limitations. The study sample was from one hospital in Shanghai, and patients were assessed during 2012 to 2013. This study was conducted based on several scales, which might not be all-inclusive. The study only covered the first 3 months of treatment. Because of the retrospective nature of the study, many factors could not be evaluated, including compliance with medication. Losses to follow-up mostly occurred within 2 weeks from the first day of diagnosis. After 2 weeks, the sample size was relatively small for analysis. Patients who were lost to follow-up were contacted to assess the reasons for loss to follow-up; because they were told at their first visit that this would happen, most patients were cooperative but it is possible that some did not cooperate. The survey was not formally validated. In this study, we failed to examine the effects of different antidepressants on the follow-up rate, even though some studies have indicated that different antidepressant medications affect patients’ medication adherence. In the present study, the assessors conducting the survey were blinded to treatments, which could partly overcome this limitation. Finally, not all factors were related to the patient; some factors were related to the physician and others to the patient–physician relationship. Nevertheless, in psychiatry, treatment of a patient often cannot be dissociated from the patient’s relationship with their physician.

In conclusion, patients with high follow-up adherence were relatively older and had higher HAMD scores. Globally, the main reason for loss to follow-up was fear of adverse effects and the belief that depression cannot or should not be cured using drugs. The main reason for loss to follow-up after 2 weeks of treatment for depression was feeling that the drug was effective and no longer needed.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
This paper was supported by a Shanghai Municipal Health Bureau’s Subject (Subject title: An investigation on reasons for outpatient depression patient’s dropout and an evaluation
of interventions targeted to control the dropout rate. Subject code: 20134147).

ORCID iD
Chenyu Ye https://orcid.org/0000-0002-5146-2681

References

1. Gu L, Xie J, Long J, et al. Epidemiology of major depressive disorder in mainland China: a systematic review. PLoS One 2013; 8: e65356.
2. Gautam S, Jain A, Gautam M, et al. Clinical practice guidelines for the management of depression. Indian J Psychiatry 2017; 59: S34–S50.
3. Stein-Shvachman I, Karpas DS and Werner P. Depression treatment non-adherence and its psychosocial predictors: differences between young and older adults? Aging Dis 2013; 4: 329–336.
4. Sirey JA, Banerjee S, Marino P, et al. Adherence to depression treatment in primary care: a randomized clinical trial. JAMA Psychiatry 2017; 74: 1129–1135.
5. Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. Nat Rev Dis Primers 2016; 2: 16065.
6. Work Group on Major Depressive Disorder. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Washington, D.C.: American Psychiatric Association, 2010.
7. NICE. Depression in adults: recognition and management. London: National Institute for Health and Care Excellence, 2009.
8. Park MJ, Yamazaki Y, Yonekura Y, et al. Predicting complete loss to follow-up after a health-education program: number of absences and face-to-face contact with a researcher. BMC Med Res Methodol 2011; 11: 145.
9. Vergouwen AC, Burger H, Verheij TJ, et al. Improving patients’ beliefs about antidepressants in primary care: a cluster-randomized controlled trial of the effect of a depression care program. Prim Care Companion J Clin Psychiatry 2009; 11: 48–52.
10. Ho SC, Jacob SA and Tangiisuran B. Barriers and facilitators of adherence to antidepressants among outpatients with major depressive disorder: a qualitative study. PLoS One 2017; 12: e0179290.
11. Burra TA, Chen E, McIntyre RS, et al. Predictors of self-reported antidepressant adherence. Behav Med 2007; 32: 127–134.
12. Zhang L, Chen Y, Yue L, et al. Medication use patterns, health care resource utilization, and economic burden for patients with major depressive disorder in Beijing, People’s Republic of China. Neuropsychiatr Dis Treat 2016; 12: 941–949.
13. Hung CI, Wang SJ, Liu CY, et al. Comorbidities and factors related to discontinuation of pharmacotherapy among outpatients with major depressive disorder. Compr Psychiatry 2011; 52: 370–377.
14. Novick D, Montgomery W, Moneta V, et al. Antidepressant medication treatment patterns in Asian patients with major depressive disorder. Patient Prefer Adherence 2015; 9: 421–428.
15. Yau WY, Chan MC, Wing YK, et al. Noncontinuous use of antidepressant in adults with major depressive disorders - a retrospective cohort study. Brain Behav 2014; 4: 390–397.
16. Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV). Washington: American Psychiatric Association, 1994.
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62.
18. Zheng YP, Zhao JP, Phillips M, et al. Validity and reliability of the Chinese Hamilton Depression Rating Scale. Br J Psychiatry 1988; 152: 660–664.
19. Lee HC, Chiu HF, Wing YK, et al. The Zung Self-rating Depression Scale: screening for depression among the Hong Kong Chinese elderly. J Geriatr Psychiatry Neurol 1994; 7: 216–220.
20. Wu WY. Self-Rating Anxiety Scale. In: ZJ Zhang (ed.) Behavioral medicine inventory manual. Beijing: The Chinese Medicine Electronic Audio and Video Publishing House, 2005.
21. Zhang J and Zhang X. Chinese college students’ SCL-90 scores and their relations to college performance. *Asian J Psychiatr* 2013; 6: 134–140.

22. van Schaik DJ, Klijn AF, van Hout HP, et al. Patients’ preferences in the treatment of depressive disorder in primary care. *Gen Hosp Psychiatry* 2004; 26: 184–189.

23. Sawada N, Uchida H, Suzuki T, et al. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. *BMC Psychiatry* 2009; 9: 38.

24. Kleinman A and Kleinman J. Comatization: the interconnections in Chinese Society among culture, depressive experiences, and the meanings of pain. In: A Kleinman and B Good (eds) *Culture and depression studies in the anthropology and cross-cultural psychiatry of affect and disorder*. Berkeley: University of California Press, 1985.

25. Lu Y, Arthur D, Hu L, et al. Beliefs about antidepressant medication and associated adherence among older Chinese patients with major depression: a cross-sectional survey. *Int J Ment Health Nurs* 2016; 25: 71–79.

26. Lee MS, Lee HY, Kang SG, et al. Variables influencing antidepressant medication adherence for treating outpatients with depressive disorders. *J Affect Disord* 2010; 123: 216–221.

27. Yen CF, Lee Y, Tang TC, et al. Predictive value of self-stigma, insight, and perceived adverse effects of medication for the clinical outcomes in patients with depressive disorders. *J Nerv Ment Dis* 2009; 197: 172–177.

28. Chong WW, Aslani P and Chen TF. Effectiveness of interventions to improve antidepressant medication adherence: a systematic review. *Int J Clin Pract* 2011; 65: 954–975.

29. Shiner B, Green RL, Homa K, et al. Improving depression care in a psychiatry resident psychopharmacology clinic: measurement, monitoring, feedback and education. *Qual Saf Health Care* 2010; 19: 234–238.